These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34270976)

  • 1. Optimized cytotoxicity assay for co-suspended effector and target cells.
    Cui L; Yin F; Cheng J; Liu H; Zheng M; Liu D; Wu Z; Qian Q
    J Immunol Methods; 2021 Oct; 497():113100. PubMed ID: 34270976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
    Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
    Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro CAR-T cell killing: validation of the potency assay.
    Piccinini C; Carloni S; Arienti C; Pancisi E; Fanini F; Pignatta S; Soldati V; Stefanelli M; Granato AM; Martinelli G; Ridolfi L; Petrini M
    Cancer Immunol Immunother; 2024 Jul; 73(9):168. PubMed ID: 38953939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells
    Valentine M; Li L; Zhou H; Xu S; Sun J; Liu C; Harto H; Berahovich R; Golubovskaya V; Wu L
    Front Biosci (Landmark Ed); 2020 Jan; 25(2):270-282. PubMed ID: 31585889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2021; 12():670088. PubMed ID: 34122428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
    Anna F; Bole-Richard E; LeMaoult J; Escande M; Lecomte M; Certoux JM; Souque P; Garnache F; Adotevi O; Langlade-Demoyen P; Loustau M; Caumartin J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of non-genetically modified, CAR-like, NK cells.
    Coënon L; Rigal E; Courot H; Multrier C; Zemiti S; Lambour J; Pugnière M; de Toledo M; Bossis G; Cartron G; Robert B; Martineau P; Fauvel B; Presumey J; Villalba M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells.
    Eugene-Norbert M; Cuffel A; Riou G; Jean L; Blondel C; Dehayes J; Bisson A; Giverne C; Brotin E; Denoyelle C; Poulain L; Boyer O; Martinet J; Latouche JB
    J Immunol Methods; 2024 Feb; 525():113603. PubMed ID: 38147898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.
    Maldini CR; Love AC; Tosh KW; Chan LL; Gayout K; Smith T; Riley JL
    J Immunol Methods; 2020; 484-485():112830. PubMed ID: 32745474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human NK-92 Cells Function as Target Cells for Human NK Cells - Implications for CAR NK-92 Therapies.
    Bergman H; Sissala N; HÄgerstrand H; Lindqvist C
    Anticancer Res; 2020 Oct; 40(10):5355-5359. PubMed ID: 32988854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.